Results:

Private and Public Partners Unite to Combat 10 Neglected Tropical Diseases by 2020

30 01 2012

Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade. Uniting efforts with NTD-endemic countries, partners pledged to […]


Study Grades Companies’ Political Transparency: Berkshire Hathaway, Disney Rank Lowest

2 11 2011

A new study conducted by the non-profit, non-partisan Center for Political Accountability with the Zicklin Center at University of Pennsylvania examines how major businesses spend money to influence politics. The study identified a total of 29 indicators to gauge disclosure, policies, compliance and oversight of all of the top S&P 100 companies in order to assess companies on […]


Glaxo, Merck Support Effort to Boost Vaccine Access

6 06 2011

GlaxoSmithKline Plc and Merck & Co. agreed to lower prices for vaccines to protect children against potentially deadly diarrhea, supporting an international effort to help least-developed nations fight diseases. The GAVI Alliance, set up by Microsoft Corp. founder Bill Gates to give the world’s poorest people better access to life- saving immunizations, also received commitments […]


Merck Gets Religion, Embraces Transparency

19 10 2009

The big drugmaker follows the recent step by Eli Lilly (see here) to add a spot on its website where inquiring minds can find just how much is paid to doctors for speaking engagements. “Our reputation, and the trust that our customers place in us, depend in large part on how we conduct ourselves as […]


Physician Payment Sunshine: Merck Joins the Act

26 09 2008

In a move to give the public more transparency around physician payments and grants Merck announced that starting in October 2008, Merck will be posting their grants (including CME, patient and Medical Specialty Society Grants) on their home page www.merck.com; in 2009 they will be disclosing payments to physicians who speak on their behalf; and […]


Pharmas Challenged by Product Risk and Philanthropy Fatigue – Covalence Pharmaceutical Industry Report 2008

9 09 2008

Increased attention on product human risk and smaller media coverage of drug donations have challenged Pharmaceuticals’ ethical reputation last year, states a report published today by Geneva-based research firm Covalence — Covalence Pharmaceutical Industry Report 2008. The pharmaceutical industry dropped from the first to the third rank of Covalence all-time EthicalQuote ranking across 10 industries. […]


Cameroun : Merck distribue une nouvelle classe d’antirétroviraux(ARV) aux malades du sida

6 08 2008

Pour parer au problème de résistance aux ARV dont de plus en plus de patients camerounais font face, les laboratoires Msd (Merck Sharp and Dhome) ont mis sur pied une nouvelle classe d’Arv. Il s’agit du Raltegravir ou Isentress (nom commercial) distribué gratuitement dans les hôpitaux et Centres de santé du pays. Cette molécule agit […]


Merck Wins Appeal of First VIOXX Case to go to Trial

29 05 2008

WHITEHOUSE STATION, N.J., May 29, 2008 – Merck & Co., Inc. said today that it is gratified that a Texas appeals court overturned the August 2005 verdict of a state court jury in Brazoria County and rendered a judgment in favor of Merck in the VIOXX product liability case Ernst v. Merck. It was the […]


The poor stand to lose from anti-patent crusades

30 04 2008

Should poor governments be allowed to break drug patents for humanitarian reasons? That question is front-and-center at a major public health conference sponsored by the World Health Organization that started on 28 April in Geneva. Top-notch policy experts from around the world have gathered to make formal policy recommendations about patents to Third World governments […]


Innovation et philanthropie dopent le marché des vaccins

8 01 2008

En 2007, le laboratoire américain Merck a supplanté Sanofi Aventis à  la tàªte du classement mondial des producteurs de vaccins. GlaxoSmithKline (GSK), qui talonnait Sanofi, se retrouve donc numéro trois. Sur les neuf premiers mois de 2007, Merck a réalisé 2,13 milliards d’euros de chiffre d’affaires, son dauphin Sanofi Aventis 2,12 milliards et GSK 1,9 […]